Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on Sep 08, 2010 4:00pm
428 Views
Post# 17426072

RE: RE: Innuendo.

RE: RE: Innuendo.
You just don't get it Gemini, you seem to have a difficult time figuring people out always they have to have an agenda. I'm glad Haititrader is so obvious to you because I don't understand him at all! Since I don't understand him, I don't have any interest in giving him credibility.  I like to have a peacefull board,

I really like the way the stock is acting at the moment, in my opinion we are right on top of a financing yet we are strong. I certainly would say a strong hold for any shareholders, but for prospective shareholders it's difficult for me I see another chance to buy after financing for significantly less and before more results come in. I think we will test three again, I believe that the trial will run slow and we will not see the first results until the middle of next year considerable later than Brad said. So really I would say buy shortly after financing is announced but I  would not want to be out when first results from lung cancer come in later in the year. As for partnership Brad has been sounding like a broken record for over a year, I'm convinced he is taking this to first results to get the best price and I don't  think I disagree.

I've explained it before to you but you don't believe me. I'm very bullish on the chances of success in phase three with squamous cell of the head and neck. I like Oncolytics but I have issues with Brad over the years which does effect my posts. He has disappointed me a number of times in the past and the smart  thing to have done over the years would have been to trade the stock and I feel stupid about it,  but I'm an investor and not a trader. The one good thing is we are so close now that it would be risky to trade the stock now.
 
I have learned one thing about biotechs I no longer invest in early stage biotechs have learned my lesson only late stage two or early stage three companies for me.
Bullboard Posts